SCHEMBL22042

SCHEMBL22042

NC(=O)CC[C@H](NCCO)C(=O)O

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.45
ALOX15 P16050 1/20 0.45
BLM P54132 1/20 0.45
PMP22 Q01453 1/20 0.45
GGT1 P19440 1/20 0.43
MMP2 P08253 2/20 0.41
MMP9 P14780 2/20 0.41
CA2 P00918 5/20 0.40
CA1 P00915 4/20 0.40
FOLH1 Q04609 3/20 0.38
RIMKLA Q8IXN7 1/20 0.38
NAALAD2 Q9Y3Q0 1/20 0.38
NOD1 Q9Y239 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
TGFBR1 P36897 1/20 0.37
ACE P12821 1/20 0.33
BMP1 P13497 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1226472 1.00 KMT2A (0.45) KMT2AALOX15BLMPMP22GGT1
SCHEMBL6156358 1.00 KMT2A (0.45) KMT2AALOX15BLMPMP22GGT1
Trifluoroacetic Acid SCHEMBL28454353 0.90 KMT2A (0.38) KMT2AALOX15BLMPMP22GGT1
SCHEMBL1002209 0.89 KMT2A (0.42) KMT2AALOX15BLMPMP22GGT1
SCHEMBL9724019 0.89 KMT2A (0.42) KMT2AALOX15BLMPMP22GGT1
SCHEMBL149082 0.88 KMT2A (0.48) KMT2AALOX15BLMPMP22GGT1
SCHEMBL3364090 0.87 NOD1 (0.42) KMT2AALOX15BLMPMP22GGT1
SCHEMBL27546900 0.87 NOD1 (0.42) KMT2AALOX15BLMPMP22GGT1
Glutamic Acid SCHEMBL8219043 0.87 ALOX15 (0.56) KMT2AALOX15BLMPMP22FOLH1
SCHEMBL3652208 0.87 NOD1 (0.44) KMT2AALOX15BLMPMP22GGT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 727 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025262234-A1 BIOADHESIVE MICROPARTICLE FORMULATIONS NATIONAL UNIVERSITY OF IRELAND, GALWAY (IE) 2025-12-26 WO claimed
WO-2025242657-A1 LIPOPEPTIDE BUILDING BLOCKS AND AGGREGATES SHAPE BIOPHARMACEUTICALS AG (CH) 2025-11-27 WO claimed
CN-119722363-A Social network community information hiding method and device guided by structural information 杭州市滨江区浙工大人工智能创新研究院 2025-03-28 CN claimed
US-12188021-B2 C5a binding nucleic acids APTARION BIOTECH AG (DE) 2025-01-07 US claimed
US-20240384275-A1 C5a Binding Nucleic Acids APTARION BIOTECH AG (DE) 2024-11-21 US claimed
CN-118680883-A Loadable porous structure for use as an implant 瑞艾克斯制药公司 2024-09-24 CN claimed
US-12049520-B2 Bicyclic peptide ligands specific for CD137 BICYCLETX LIMITED (GB) 2024-07-30 US claimed
CN-111183147-B CD137 specific bicyclic peptide ligands 拜斯科技术开发有限公司 2024-07-05 CN claimed
US-11998562-B2 Ophthalmological formulations for the prevention of a coronavirus infection UNIVERSITY OF SOUTH FLORIDA (US) 2024-06-04 US claimed
CN-117247421-A Preparation process of high-content ligustrum lucidum glycoside and osmanthus fragrans standard active substance 上海香泉里生物科技有限公司 2023-12-19 CN claimed
US-6312727-B1 SYNTHETIC POLYMER CARRIER VEHICLE FOR DELIVERY OF NUCLEIC ACID TO TARGET CELLS IN BIOLOGICAL SYSTEMS HYBRID SYSTEMS LIMITED (GB) 2001-11-06 US claimed
EP-1088020-A1 FUNCTIONALISED POLYMERS OF ALPHA-AMINO ACIDS AND THE METHOD OF PREPARATION THEREOF USTAV MAKROMOLEKULARNI CHEMIE AKADEMIE VED CESKE REPUBLIKY (CZ) 2001-04-04 EP claimed
WO-2000074722-A2 MODIFICATION OF BIOLOGICAL ELEMENTS HYBRID SYSTEMS LIMITED (GB) 2000-12-14 WO claimed
EP-0804246-B1 DRUG DELIVERY AGENTS INCORPORATING MITOMYCIN EUROP ECONOMIC COMMUNITY (LU) 2000-05-17 EP claimed
WO-1999064495-A1 FUNCTIONALISED POLYMERS OF α-AMINO ACIDS AND THE METHOD OF PREPARATION THEREOF ÚSTAV MAKROMOLEKULÁRNÍ CHEMIE AKADEMIE VĚD ČESKÉ REPUBLIKY (CZ) 1999-12-16 WO claimed
US-5738864-A COVALENT COUPLING THROUGH LINKING SPACER GROUPS TO MACROMOLECULES THAT CAN SERVE AS RELATIVELY INERT POLYMERIC DRUG CARRIERS IN BIOLOGICAL SYSTEMS; SIDE EFFECT REDUCTION EUROPEAN COMMUNITY (DE) 1998-04-14 US claimed
EP-0804246-A1 DRUG DELIVERY AGENTS INCORPORATING MITOMYCIN Commission of the European Communities (LU) 1997-11-05 EP claimed
WO-1995005200-A1 DRUG DELIVERY AGENTS INCORPORATING MITOMYCIN EUROPEAN COMMUNITY (LU) 1995-02-23 WO claimed
EP-0213996-B1 RAMIFIED POLYMERS BASED ON LIPOPEPTIDES FORMING THERMOTROPIC AND LYOTROPIC LIQUID CRYSTALS, THEIR USE AND CORRESPONDING MONOMERS CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 1989-09-06 EP claimed
US-4859753-A EMULSIFIERS, FOAMING AGENTS CENTRE NATIOONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 1989-08-22 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12049520-B2 Bicyclic peptide ligands specific for CD137 CD2BP2, CD40, SDC1 KMT2A 4692/4885ALOX15 3774/4885BLM 4274/4885
US-11998562-B2 Ophthalmological formulations for the prevention of a coronavirus infection SARS1, ACE, ACE2 KMT2A 4619/4885ALOX15 610/4885BLM 45/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.